New hope for bladder cancer: TRAIN trial tests radiotherapy against standard BCG

NCT ID NCT07268339

Not yet recruiting Disease control Sponsor: The Christie NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Apr 24, 2026 · Updated 19 times

Summary

This study tests if a combination of radiotherapy and a radiosensitising drug works better than the standard BCG immunotherapy for people with high-risk non-muscle invasive bladder cancer. About 328 participants will be randomly assigned to receive either BCG or radiotherapy with a radiosensitiser. The goal is to see which treatment better prevents the cancer from coming back or getting worse, while also monitoring side effects and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The Christie

Manchester, M20 4BX, United Kingdom

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER